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Endogenous analogues of capsaicin, N-acyldopamines, were previously identified from striatal extracts,
but the putative presynaptic role of their receptor, the TRPV1R (formerly: vanilloid or capsaicin
receptor) in the caudate–putamen is unclear. We found that the endogenous TRPV1R agonists, N-
arachidonoyldopamine (NADA) and oleoyldopamine (OLDA) with EC50 values in the nanomolar range, as
well as the synthetic TRPV1R activator 2-aminoethoxydiphenylborane (2APB), and palmytoyldopamine
(PALDA, another endogenous N-acyldopamine inactive at the TRPV1R), but not capsaicin or other
endogenous and synthetic cannabinoids, triggered a rapid Ca2þ entry with the concomitant stimulation
of glutamate and dopamine release. These effects persisted in the TRPV1R null-mutant mice, and were
insensitive to antagonists of common ionotropic receptors, to several TRPV1R antagonists and to the
absence of Kþ. Furthermore, these N-acyldopamine receptors in glutamatergic and dopaminergic
terminals are different based on their different sensitivity to anandamide, capsazepine and Gd3þ at
nanomolar concentrations. Altogether, novel ion channels instead of the TRPV1R mediate the presynaptic
action of N-acyldopamines in the striatum of adult rodents.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
The transient receptor potential vanilloid type-1 receptor
(TRPV1R) is a non-selective Ca
2þ and Naþ channel activated by heat,
protons, inflammatory agents, endovanilloids and the pungent
substance, capsaicin of chilli pepper, and is involved in peripheral
and central pain transmission and procession (Caterina et al., 1997;
Avelino and Cruz, 2006; Nagy et al., 2008). The so-called endova-
nilloids are diverse lipidomics (mostly arachidonate-derivatives)
(Starowicz et al., 2007), and among them, perhaps anandamide
(arachidonoylethanolamine, AEA, Fig. 1C) is the most studied as it
also activates the inhibitory metabotropic type-1 cannabinoid
receptor (CB1R) (Devane et al., 1992; Lovinger, 2008). N-arach-
idonoyldopamine (NADA) is another endogenous ligand capable of
activating both theCB1R and the TRPV1R, and belongs to the recently
described family of N-acyldopamines (Starowicz et al., 2007).
Several similar fatty acid dopamide conjugates have been identified: þ351 239 822776.
All rights reserved.in striatal extracts, among which NADA and N-oleoyldopamine
(OLDA) (Fig. 1C) are as efficacious and potent as capsaicin at the
TRPV1R (Huang et al., 2002; Chu et al., 2003). However, the obser-
vation that palmytoyldopamine (PALDA; Fig. 1C) lacks agonist
activity at the TRPV1R (Chu et al., 2003) prompts the hypothesis that
N-acyldopamines may have additional targets.
In the brain, TRPV1Rs display higher density in the cortex, the
hippocampus, the preoptic area, the medial basal hypothalamus,
the locus coeruleus and the basal ganglia (Mezey et al., 2000;
Sanchez et al., 2001; Szabo´ et al., 2002; Roberts et al., 2004; To´th
et al., 2005; Cristino et al., 2006). Marinelli et al. (2003, 2005, 2007)
found that TRPV1R activation can directly stimulate dopamine
release or glutamatergic transmission in the substantia nigra pars
compacta, the ventral tegmental area and the nucleus accumbens
of the rat. In the striatum, presynaptic TRPV1Rs desensitize rapidly,
but the activation of protein kinase C (PKC) unmasks TRPV1R-
mediated presynaptic facilitatory actions (Musella et al., 2009).
Thus, in the absence of PKC activation, predominantly post-
synaptic TRPV1R activation can be detected which down-regulates
the post-synaptic release of 2-arachidonoylglycerol (2-AG)
(Maccarrone et al., 2008). Importantly, 2-AG (Fig. 1C) is another
Fig. 1. Nicotine and N-acyldopamines induce Ca2þ transients in striatal nerve terminals. Nerve terminals were loaded with Fura2/AM, and left for 4 min in the cuvette for
stabilization under stirring. The first 90 s represents the pre-treatment period, and subsequently, 2 ml of vehicle or drugs was administered. Emission values were collected at 2-s
intervals and expressed as nM. The average of the two everyday control values was subtracted from the treatments and displayed as net drug effect in panels A and B. A) The
classical striatal excitant, nicotine, triggers rapid [Ca2þ]i rise in a concentration-dependent fashion. For the sake of simplicity, only the average of the nicotine (100 mM) experiments
is presented with error bars (panel A). B) The endogenous TRPV1R agonist, NADA (continuous line) but not the botanical TRPV1R activator, capsaicin (dashed line) triggers rapid
[Ca2þ]i which is only partially prevented by the TRPV1R antagonist, capsazepine (CPZ, 10 mM), dotted line. C) Chemical structure of N-acyldopamines and endocannabinoids used
throughout the study. D) Concentration–response curves for ligands tested in the fluorimetric assay. Note that 2-AG and WIN55212-2 absorb more light at 340 than at 380 nm
falsely diminishing Ca2þ level readings, therefore, these values are not displayed in the graph (for more information, see Section 2, Table 1, and the 2nd paragraph of Section 3). All
points represent mean  S.E.M. of n  6 different observations in duplicate. *p < 0.05.
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synapse (Stella et al., 1997; Lovinger, 2008); hence post-synaptic
TRPV1R activation may set free glutamatergic terminals from CB1R-
mediated inhibitory control.
Based on these observations, one would expect that TRPV1R
activation causes hyperkinesia either by decreasing 2-AG release
locally in the striatum or by increasing glutamate and/or dopamine
release via the activation of the striatal afferents. Surprisingly, the
opposite is the case: TRPV1R agonists, either systemically or locally
administered, induce hypokinesia and decrease nigrostriatal
activity and striatal DOPAC content, inasmuch as TRPV1R antago-
nists induce hyperactivity (Di Marzo et al., 2001; de Lago et al.,
2004; Tzavara et al., 2006). Thus, these controversial data invite
further studies since the role of the endovanilloid system in neu-
romodulation and in neurological and psychiatric disorders has
been emerging.
In this present study, we aimed at analyzing the presynaptic role
of capsaicin, anandamide, NADA and OLDA in a relevant brain area,
namely, the striatum. We used nicotine as a positive control, and
PALDA as a negative one. Our goal was to monitor the dynamics of
intrasynaptosomal Ca2þ level changes upon administration of
vanilloid ligands, together with their potency and efficacy to induce
glutamate and dopamine release.2. Methods
2.1. Preparation of synaptosomes
All studies were conducted in accordance with the principles and procedures
outlined in the EU guidelines and were approved by the local Animal Care
Committee of the Institute. All efforts were made to reduce the number of animals
used and to minimize their suffering. Therefore all rats (male Wistar rats, 140–160 g,
6–8-week old, vendor: Charles-River, Barcelona, Spain) and wild-type mice (C57bl/
6, 10–12-week old, vendor: Charles-River, Barcelona, Spain) and genotyped TRPV1R
null-mutant mice (C57bl/6, 10–12-week old, vendor: The Jackson Laboratory) were
anesthetized with halothane before being decapitated. Striata from two rats (fluo-
rimetry) or one rat or one mouse (45Ca2þ uptake assay and [14C]glutamate and
[3H]DA release assay) were quickly removed into ice-cold sucrose solution (0.32 M,
containing 5 mM HEPES, pH 7.4) and were homogenized instantly with a Teflon
homogenizer, and centrifuged at 5000 g for 4 min. The supernatant was centrifuged
at 13,000 g for 10 min. The mitochodrium-free fraction of the pellet was collected
and washed at 13,000 g for 2 min in 45% Percoll solution at 4 C, then decanted and
stored sealed on ice.2.2. Fluorimetric assay
Experiments were performed as described by us earlier (Ko¨falvi et al., 2007):
synaptosomal pellets (w1 mg protein) were preincubated with Fura2/AM (5 mM) for
15 min at 25 C in the incubation solution of the following composition: NaCl
(132 mM), KCl (1 mM), MgCl2 (1 mM), CaCl2 (0.1 mM), H3PO4 (1.2 mM), glucose
(10 mM), HEPES (10 mM), pH 7.4. Then the pellet was centrifuged at 13,000 g,
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MgCl2 (1.2 mM), CaCl2 (2.5 mM), H3PO4 (0.4 mM), glucose (10 mM), HEPES (10 mM),
pH 7.4]. After the 4 min stabilization period at 37 C, data were collected with 2-s
intervals by a computer-assisted spectrofluorometer (Fluoromax, Spex Industries,
Edison, NJ) at 510 nm emission and double excitation at 340 and 380 nm, with
1.175 nm slits. The first 90 s represented the pre-treatment period, and then 2 ml of
the stock drug solutions was applied. The calibrationwas done 70 s later, using 5 mM
ionomycin (Rmax), and 30 s later, 10 mM EGTA/30 mM TRIS, pH 9.6 (Rmin). The
fluorescence intensities were converted into [Ca2þ]i values by using the calibration
equation for double excitation wavelength measurements and taking the dissocia-
tion constant of the Fura2/Ca2þ complex as 224 nM (Grynkiewicz et al., 1985).
2.3. Calculation
In each experiment, vehicle controls and treatments were performed in dupli-
cate. The average of the daily vehicle controls was subtracted from the average of the
treatments. Then, a forecast line was fitted to the first 45 data points (representing
the 90 s pre-treatment period) with linear regression. Drug effects were calculated
as the change in [Ca2þ]i (nM)/min, compared to the forecast line with the area under
the curve method.
2.4. Effect of drugs on absorbance and emission
Table 1 summarizes the absorbance and the emission values of tested ligands at
the highest used concentrations. Capsaicin (1 mM) and 2-arachidonoylglycerol
(2-AG, up to 3 mM) do not absorb at 340 and 380 nm; anandamide (AEA, 10 mM),
R-methanandamide (RmAEA, 10 mM), and N-arachidonoyldopamine (NADA, 10 mM)
significantly but equally absorb at the two wavelengths resulting in ratios not
significantly different from ethanol control. However, the CB1R agonists, WIN55212-
2 (1 mM: by 18.2 0.24%; 10 mM: by 45.10.12%; n¼ 6, p< 0.001) and 2-AG (10 mM:
by 4.1  0.29%; n ¼ 6, p < 0.001) already significantly absorbed more at 340 nM
diminishing the Intensity340/Intensity380. As a consequence, when applied in the
cuvette, WIN55212-2 and 2-AG (10 mM) induced an artificial decrease of in the
Fura2bound/Fura2free ratio which had to be corrected during the calculation of [Ca
2þ]i,
based on the equation of Grynkiewicz et al. (1985). The emission ofWIN55212-2 and
2-AG was determined by the use of a Spex spectrofluorometer. Cuvettes were filled
with 2 ml of milliQ water to determine the emission of 510 nm light at 340 and
380 nm excitation, and subsequently vehicle (ethanol) or the tested compound
(with the same amount of vehicle) was applied, and results from six independent
observations were averaged. As a consequence that 2-AG significantly absorbs more
light at 340 than at 380 nm it decreases the Em340/Em380 ratio significantly and
concomitantly, falsely diminishes [Ca2þ]i readings.
2.5. 45Ca2þ uptake assay
Experiments were carried out in the samemanner (timing, conditions, and assay
solutions) as in the fluorimetric assay. Synaptosomal aliquots of 50 ml (w1–2 mg)
were diluted to 600 ml in the assay solution and kept at 37 C for 5 min. Then 400 ml
of pre-warmed assay solution containing 45Ca2þ (isotope purchased from Perki-
nElmer) and the vehicle or drug tested was added to the synaptosomes. The final
concentration of the isotopewas 0.5 mCi/ml. Sixty second later, 1 ml of ice-cold Ca2þ-
free assay solution containing 10 mM EGTA/30 mM TRIS (pH 9.6) was added to stop
reactions and the samples were vacuum-filtered immediately in GF/B filters. TheTable 1
Optical density values at 340 and 380 nm and emission values at 510 nm wave-
lengths of cannabinoid and vanilloid ligands used in fluorimetry.
Treatment OD340 OD380 Ratio
CTRL (vehicle) 52.0  0.8 41.7  0.2 100%
AEA (10 mM) 76.7  1.6* 61.7  1.4* 100.3% n.s.
RmAEA (10 mM) 71.7  2.2* 57.3  1.8* 99.8% n.s.
2-AG (3 mM) 51.7  0.6 41.0  0.7 100.3% n.s.
2-AG (10 mM) 65.7  0.6* 49.3  0.5* 94.9%*
WIN (0.3 mM) 50.0  0.4 39.0  0.4 98.6%
WIN (1 mM) 69.0  0.4* 44.7  0.2* 81.8%*
WIN (10 mM) 128.8  0.4* 57.7  0.2* 56.9%*
2APB (100 mM) 49.5  0.8 40.3  0.9 101.0% n.s.
NADA (10 mM) 137.0  2.3* 112.0  0.4* 102.0% n.s.
OLDA (10 mM) 55.0  1.6 43.7  1.0 98.6% n.s.
PALDA (10 mM) 52.0  0.8* 42.3  0.6* 99.0% n.s.
Capsaicin (1 mM) 49.3  0.8 39.7  1.0 100.2% n.s.
Treatment Em340 % of CTRL Em380 % of CTRL Ratio
CTRL (vehicle) 100% (3942  91 cpm) 100% (3117  67 cpm) 100%
2-AG (10 mM) 167.1  1.0%* 193.1  2.4%* 86.6%*
*P < 0.05[45Ca] content of each samplewas counted by a Tricarb b-counter (PerkinElmer), and
expressed as D[Ca2þ] (nM/mg protein).
2.6. Dual-label [3H]DA/[14C]glutamate release assay from striatal nerve terminals
Experiments were carried out as before (Ko¨falvi et al., 2007). Striatal synaptosomes
were diluted to 3mlwithKrebs’ solution (inmM:NaCl 113, KCl 3, KH2PO41.2,MgSO41.2,
CaCl2 2.5, NaHCO3 25, glucose 10, oxygenated with 95% O2, and 5% CO2, pH 7.4, 37 C),
and equilibrated for 5 min. After this, 20 mCi of [14C]glutamate (PerkinElmer) and 10 mCi
of [3H]dopamine (GE Healthcare) were added to the synaptosomes for 10 min. All
solutions contained the glutamate decarboxylase inhibitor aminooxyacetic acid
(100 mM) and the MAO-B inhibitor pargyline (10 mM). A 16-microvolume chamber
perfusion setup was filled with the preloaded synaptosomes which were trapped by
layers ofWhatmanGF/C filters and superfused continuously at a rate of 0.7ml/min until
the endof the experimentwith oxygenatedKrebs’ solution at 37 C.Upon termination of
the 15-minwashout, 2-min sampleswere collected for liquid scintillation assay, and the
filters were also harvested to obtain the total radioactivity content. In each experiment,
treatments were applied in quadruplicate (i.e. 4 chambers served as control averaged as
n¼ 1 and three other treatmentswere applied in the rest of the 3-times4 chambers). All
drugs were perfused from the 6th min of sample collection for 3 min. High Kþ was
applied as isomolar substitution of Naþ by Kþ in the buffer. The proportion of dopamine
and glutamate in the released radioactivity was confirmed to be >95%, as previously
reported (Ko¨falvi et al., 2007). The [14C] and [3H] contents of each sampleswere counted
by dual-label protocol by a Tricarb b-counter (PerkinElmer), and DPM values were
expressed as fractional release (FR%), i.e. the percent of actual content in the effluent in
the function of the total synaptosomal content (for details see Ko¨falvi et al., 2007).
2.7. Data treatment
All data represent mean  SEM of n  5 observations. After subtracting the
respective control value from the effect of treatment, statistical significance was
calculated by column statistics (difference from the hypothetical value of zero if the
question was whether a treatment has had any effect or not), Student’s t-test or
ANOVA followed by Bonferroni’s test. A p < 0.05 was accepted as significant
difference.
2.8. Drugs
HEPES, WIN55212-2, sucrose, aminooxyacetic acid, nicotine, sulpiride, and
ionomycin were obtained from Sigma, Saint Louis, Missouri, USA. Arach-
idonoylethanolamide (anandamide, AEA), 2-arachidonoylglycerol (2-AG), SB366791,
2-aminoethoxydiphenylborane (2APB), Ruthenium Red, iodoresiniferatoxin (IRTX),
AM251, (þ)-tubocurarine chloride, and pyridoxalphosphate-6-azophenyl-20 ,40-
disulfonic acid tetrasodium salt (PPADS) were obtained from Tocris Bioscience, UK.
N-arachidonoyldopamine (NADA), N-oleoyldopamine (OLDA), palmytoyldopamine
(PALDA), nifedipine, D-()-2-amino-5-phosphonopentanoic acid (D-AP5), CNQX, and
()-bicuculline methobromide were purchased from Ascent Scientific, UK. Fura2/
AM was purchased from Alfagene (Lisbon, Portugal). Non-water soluble substances
were dissolved or reconstituted in ethanol at different concentrations and aliquoted
and stored at 20 C. Stocks of cannabinoid and vanilloid agonists to be tested were
always diluted by 1000 times to have always the same concentration of vehicle in
the buffer.
3. Results
3.1. Validation of the fluorimetric assay
In rat striatal nerve terminals, the concentration of intracellular
free Ca2þ ([Ca2þ]i)was101.98.5nM(n¼76) in thebeginningof the
recording in accordance with previous studies both in whole cells
and in nerve terminals (Lauckner et al., 2005; Ko¨falvi et al., 2007). To
test the functionalityof presynaptic ligand-gated ion channels in our
experimentalmodelweused nicotine, the classical agonist of choice
in the striatum (Zhou et al., 2002). Nicotine (1–100 mM) induced
a rapidly developing and desensitizing Ca2þ transient in a concen-
tration-dependent fashion followed by a sustained but lower
elevation of [Ca2þ]i at higher nicotine concentrations (Fig. 1A,D).
3.2. N-acyldopamines, but not classical TRPV1R and/or CB1R
agonists, per se induce [Ca2þ]i rise
NADA (1–10 mM) and OLDA (0.3–10 mM) triggered an immediate,
non-desensitizing and concentration-dependent [Ca2þ]i rise. Both
substances reached the maximum effect at the concentration of
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(713 nM; calculated from the best-fit variable slope sigmoid curve)
(Fig. 1B,D). The TRPV1R antagonist, capsazepine (10 mM, added
4 min before recording) significantly diminished the NADA
(10 mM)-evoked [Ca2þ]i rise by 29.2  5.2%, n ¼ 6, p < 0.05 by
ANOVA of repeated measures test (Fig. 1B). Anandamide (AEA,
1–10 mM) and its non-metabolizing analogue, R-methanandamide
(RmAEA 0.1–10 mM) as well as capsaicin (1 mM) did not significantly
affect [Ca2þ]i up to the maximally tested concentration of 10 mM,
though D[Ca2þ]i in the presence of AEA (10 mM) was at the verge of
significance (p ¼ 0.0504; n ¼ 11 animals). As mentioned in Section
2, the CB1R agonists, WIN55212-2 (from 1 mM) and 2-AG (at 10 mM)
significantly reduce the Em340/Em380 ratio. Therefore, we needed to
re-calculate their effect on the [Ca2þ]i with modifications of the
Grynkiewicz equation. According to this calculation, 2-AG and
WIN55212-2 (0.03–10 mM) also failed to affect the [Ca2þ]i (data not
shown).
3.3. N-acyldopamines trigger 45Ca2þ uptake in striatal nerve
terminals
This assay was performed A) to test whether the [Ca2þ]i rise
represents Ca2þ entry from the extracellular buffer or originates
from intracellular Ca2þ stores; B) to validate the D[Ca2þ]i values
with direct measurement; and C) to confirm our calculations on the
lack of effect of 2-AG and WIN55212-2. Both NADA (10 mM) and
OLDA (10 mM) induced significant Ca2þ uptake with values similar
to those found with the fluorimetric assay (Fig. 2). Interestingly,
PALDA (10 mM), which is inactive at the TRPV1R, also induced a Ca
2þ
uptake of similar size. 2APB (100 mM), which is a sensitizer
(100 mM) and an activator (100 mM) of the homomeric TRPV1R,
TRPV2R, and TRPV3R (Hu et al., 2004), also induced Ca
2þ uptake
twice as large as NADA. Neither the hybrid TRPV1R/CB1R agonists,
anandamide (10 mM) and R-methanandamide (10 mM) nor the CB1R
agonists, 2-AG (10 mM) and the synthetic WIN55212-2 (1 mM)
triggered statistically significant Ca2þ uptake.Fig. 2. N-acyldopamines (each at 10 mM) and 2APB (100 mM) induce Ca2þ uptake into
striatal nerve terminals. The rest of the ligands was tested also at 10 mM except for
WIN55212-2 (WIN, 1 mM). All solutions and protocols were identical to those of the
fluorimetric assay. Upon termination of the experiment, reactions were stopped with
addition of 10 mM EGTA/30 mM TRIS (pH 9.6), then synaptosomes were immediately
vacuum-filtered and filters were counted for 45Ca2þ. The obtained values were then
converted into total (that is, radioactive þ cold) Ca2þ uptake values represented by the
figure. Values are mean þ S.E.M. of 6 rats; *p < 0.05.3.4. N-acyldopamines trigger the release of dopamine and
glutamate
To validate this neurochemical procedure, Kþ and nicotine were
employed to stimulate transmitter release. Both Kþ (10 and 15 mM)
and nicotine (100 mM) induced a rapidly developing dopamine and
glutamate release which returned to baseline upon washout
(Fig. 3A,B). Total amounts of released dopamine and glutamate
upon drug superfusion are displayed in Fig. 4. Kþ triggered the
release of glutamate and dopamine to a similar extent, while
nicotine mostly affected the release dopamine (yet, its effect on the
release of glutamate was also statistically significant) (Fig. 3A,B
and Fig. 4A).
In agreement with the fluorimetric and 45Ca2þ uptake data,
NADA, OLDA, PALDA (from as low as 1 mM) and 2APB (100 mM, the
only concentration tested) triggered the release of [3H]dopamine
and [14C]glutamate from striatal nerve terminals with the order of
efficacy of OLDAz NADA> 2APBz PALDA. At the concentration of
100 nM none of the three N-acyldopamines induced significant
transmitter release (data not shown). Capsaicin (1 and 10 mM) had
no effect on the release of either transmitter (Fig. 5B). Next, we
tested if NADA’s effect involves TASK-3 Kþ channel blockade with
the concomitant depolarization, Ca2þ entry and transmitter release
– as hypothesized before (Ko¨falvi et al., 2007). Yet, in Kþ-free
medium, the effect of NADA was unchanged (Fig. 4B). Somewhat
surprisingly, the nicotine-evoked release of dopamine (Fig. 4A)
decreased by 53% (n ¼ 5, p < 0.05) but not that of glutamate (n ¼ 5,
p > 0.05) in the absence of Kþ.
3.5. Inhibitors of TRPV channels, the CB1 receptor, and common
ionotropic receptors fail to modify the NADA-induced release of
dopamine and glutamate
Although the ion channels involved in the endovanilloids’ action
display a mixed TRPV1R and non-TRPV1R pharmacology neither the
selective and potent TRPV1R antagonists, iodoresiniferatoxin (IRTX,
1 mM) and SB366791 (1 mM) nor the non-selective TRPV1, TRPV2,
TRPV3 and TRPV4 channel blocker Ruthenium Red (10 mM) antago-
nized the effect of NADA (Fig. 4B). In contrast to hippocampal nerve
terminals (Ko¨falvi et al., 2007) Ruthenium Red did not induce
transmitter release alone indicating the lack of TASK-3 Kþ channels
in striatal dopaminergic and glutamatergic terminals (data not
shown). The putative role of another class of voltage-gated cation
channels, the L-type Ca2þ channels was investigated with the Ca2þ
channel blocker nifedipine (1 mM)which did not alter the amplitude
of NADA’s effect (Fig. 4B). As NADA being a dual CB1R/TRPV1R
agonist, we investigated tested NADA (10 mM) under CB1R blockade
by the CB1R-selective antagonist, AM251 (1 mM). AM251 did not
significantly change the amplitude of NADA’s effect on the release of
dopamineandcausedanon-significant (p¼0.106) facilitationon the
release of glutamate (n ¼ 6, Fig. 4B). Ionotropic glutamate receptor
antagonists, CNQX (50 mM) and AP-5 (10 mM); the nicotinic and 5-
HT3 receptor antagonist, tubocurarine (10 mM); the GABAA receptor
antagonist, bicuculline (10 mM); and the P2X receptor antagonist,
PPADS (10 mM) also failed to modify the action of NADA (Fig. 4C).
3.6. Anandamide, capsazepine and Gd3þ reveal different
NADA receptors
Interestingly, anandamide (10 mM) triggered a statistically
significant (though very little) release of dopamine (Fig. 3C, Fig. 5B)
but not that of glutamate (Fig. 3D). Furthermore, capsazepine,
which is a low-potency TRPV1R antagonist thought to be selective
over the other TRP channels, attenuated the effect of NADA on the
release of dopamine by 59% (n ¼ 6, p < 0.05 by ANOVA of repeated
Fig. 3. Release diagrams for the effect of Kþ, nicotine, and TRPV ligands on the release of [3H]dopamine and [14C]glutamate from rat striatal nerve terminals. Drugs or vehicle was
administered as indicated by the horizontal bar. An FR% value should be read as the amount of released transmitter as the percentage of the total nerve terminal content. For
instance, a value of 10% means that a treatment deliberated 10% of the nerve terminal content. All treatments resulted in significant transmitter release except for AEA on the release
of glutamate (denoted as n.s.; also consult with Fig. 4B,C and Fig. 5B). Values are mean þ S.E.M. of 6 rats.
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of glutamate (Fig. 4B). Recent reports showed that TRPV channels
can be inhibited by the trivalent cation Gd3þ at mid-micromolar
concentrations (as for the TRPV1R, above 100 mM) (Tousova et al.,
2005; Leffler et al., 2007). In our study, Gd3þ fully abolished the
effect of NADA, OLDA, PALDA and 2APB at a concentration as low as
3 mM (Fig. 5A,B). The ultra high potency of Gd3þ against NADA’s
effect on the release on dopamine (IC50, 745 nM) was even sur-
passed on the release of glutamate (IC50, 153 nM) (Fig. 5A). Gd
3þ
(3 mM) failed to affect the Kþ (15 mM)-evoked release of both
transmitters (data not shown).
3.7. The effect of NADA, OLDA, PALDA and 2APB persists in the
TRPV1R null-mutant mice
In the following step, we verified that the effect of the three fatty
acid dopamides (all at 10 mM) and of 2APB (100 mM) is present in
another species, thewild-type C57bl/6mice. Additionally, we found
that all four ligands triggered the release of glutamate and dopa-
mine in the TRPV1R null-mutant (‘‘knockout’’) mice, and the size of
effects was not statistically different (p > 0.05, n ¼ 5) from that in
the wild-type (Fig. 6).
4. Discussion
N-acyldopamines, NADA and OLDA, have been so far considered
as selective endogenous agonists for the TRPV1R (formerly: VR1vanilloid or capsaicin receptor) among ligand-gated ion channels
(Huang et al., 2002; Chu et al., 2003). We report now that N-acyl-
dopamines, NADA, OLDA and PALDA, posses new presynaptic
targets in the striatumwhich are linked to rapid Ca2þ entry and the
concomitant release of dopamine and glutamate. The amplitude of
effects exceeds that of nicotine and is similar to that of Kþ (15 mM)
depolarization, arguing for the significance of this novel presyn-
aptic neuromodulation mechanism in the striatum.
4.1. The suitability of our experimental models
Importantly, we have chosen to measure dopamine and gluta-
mate release as they represent the major input terminals of the
complex of the caudate–putamen nuclei. Synaptosomal prepara-
tions are the golden standard to test presynaptic neuromodulation
devoid of tonic effects and polysynaptic/glial influences (Raiteri and
Raiteri, 2000). To test presynaptic ligand-gated ion channel func-
tionality in our experimental models, we utilized nicotine, the
classical agonist of choice. Nicotine typically increases striatal
dopamine levels and consequently, stimulates locomotor activity in
rodents (Zhou et al., 2002). The two classes of nACh receptors
mediating nicotine’s effect in striatal dopaminergic terminals are
formed mostly of a4, a5, a6, b2, and b3 subunits (Salminen et al.,
2004). In our study, nicotine induced rapid Ca2þ transients in
a concentration-dependent fashion followed by a sustained but
lower elevation of [Ca2þ]i at higher nicotine concentrations. This
latter phase may be mediated by a slowly inactivating second
Fig. 4. Sensitivity of the effect of NADA to antagonists of TRPV, CB1, and common
ionotropic receptors, to lack of Kþ, and to Ca2þ channel blockade. A,B) The NADA
(10 mM)-evoked release of dopamine (black bars) and glutamate (grey bars) is greater
than that of nicotine (100 mM) and similar to that of Kþ (15 mM). In Kþ-free medium,
nicotine displayed a reduced efficacy to trigger the release of the two transmitters.
Among the TRPV channel antagonists, only capsazepine (CPZ) antagonized the effect of
NADA and only on the release of dopamine, while iodoresiniferatoxin (IRTX) and
Ruthenium Red (RuRe) failed to do so. AM251 (1 mM), the selective antagonist of the
inhibitory metabotropic CB1R, did not facilitate significantly the effect of NADA on the
release of glutamate and also left unaffected the release of dopamine triggered by
NADA. The L-type Ca2þ channel blocker nifedipine (nifed, 1 mM) did not modify the
effect of NADA on either transmitter. The effect of NADA is also unchanged in the
absence of Kþ. C) The AMPA/kainate receptor antagonist, CNQX, the NMDA receptor
antagonist, AP-5, the GABAA receptor antagonist, bicuculline (bicuc), the nACh receptor
and 5-HT3 receptor antagonist, tubocurarine, and the P2X ATP receptor antagonist,
PPADS all failed to counteract the effect of NADA. Values are mean þ S.E.M. of ¼ 6
rats ¼ 6; *p < 0.05.
Fig. 5. Sensitivity to anandamide and gadolinium reveals differences between the
receptors on dopaminergic and glutamatergic terminals. A) Gd3þ very potently inhibits
the effect of NADA in a concentration-dependent fashion, with 5-times greater potency
on the release of glutamate. B) While capsaicin (1 and 10 mM) failed to trigger trans-
mitter release, anandamide stimulated the efflux of dopamine from striatal nerve
terminals. Gd3þ (3 mM) abolished the effect of OLDA, PALDA and 2APB, respectively,
suggesting that the receptors/ion channels mediating their effects are identical to
those of NADA. Symbols: ‘‘ns’’ means that the observed release values were not
significantly different from the vehicle control. A lack of symbol above the full bars
(black bars, dopamine; grey bars, glutamate) means that the effect of the substance is
significantly different from the vehicle. # (p < 0.01) denotes that Gd3þ statistically
significantly inhibited the evoked release. Values are mean þ S.E.M. of 5 rats.
Fig. 6. High Kþ, N-acyldopamines and 2APB are equally efficacious to trigger the
release of dopamine (black bars) and glutamate (grey bars) in the C57bl/6 mice (full
bars, n¼ 5) and in the TRPV1R knockout mice (hatched bars, n ¼ 5). Note that while the
effect of Kþ (15 mM) is doubled in the mouse compared to the Wistar rat, effect
amplitudes for NADA, OLDA and 2APB are 2–2.5-times greater than in the rat, whereas
the effect of PALDA is the same (w4% release of the total releasable pool), indicating
slight species differences.
S.G. Ferreira et al. / Neuropharmacology 56 (2009) 676–683 681nAChR class. Or else, the 53% decrease in nicotine’s effect on the
release of dopamine in Kþ-free solution suggests that nAChRs
inhibited a slowly inactivating Kþ conductance, resulting in
membrane depolarization (Hamon et al., 1997).
Altogether, our neurochemical tools are able to directly
demonstrate Ca2þ transients and the consequent release of
neurotransmitters upon activation of presynaptic ligand-gated ion
channels.
4.2. N-acyldopamines activate striatal input terminals
NADA and OLDA, the two endogenous agonists of the TRPV1R,
being equipotent and equally efficacious to capsaicin, and PALDA,
which does not activate the TRPV1R (Huang et al., 2002; Chu et al.,
2003) per se triggered Ca2þ entry and the release of dopamine andglutamate. Apart from these N-acyldopamines, a non-selective
enhancer/activator of the TRPV1, TRPV2 and TRPV3 receptors, 2APB
(Hu et al., 2004), also triggered Ca2þ entry and consequently,
the release of both dopamine and glutamate. Somewhat
S.G. Ferreira et al. / Neuropharmacology 56 (2009) 676–683682contradictorily, 2APB and PALDA triggered twice as large Ca2þ
uptake but only half as much transmitter release as NADA and
OLDA did. Yet, this discrepancy can be easily resolved knowing that
2APB evokes large GABA release (shown so far only in the hippo-
campus; Ko¨falvi et al., 2006). As the striatum is the largest
GABAergic nucleus in the brain with a robust density of GABAergic
axon terminals, the effect of PALDA and 2APB on Ca2þ entry may
involve GABAergic nerve terminals too, whereas the effect of OLDA
and NADA may be more restricted to the input terminals.
4.3. N-acyldopamines depolarized striatal nerve terminals via
targets other than the TRPV1R
Notably, different concentrations of the general TRPV1R
agonists, capsaicin, anandamide and R-methanandamide did not
trigger significant [Ca2þ]i rise, Ca2þ uptake and evoked transmitter
release. This is in agreement with recent findings indicating that
PKC activation is a pre-requisite to prevent rapid TRPV1R desensi-
tization in striatal glutamatergic terminals (Musella et al., 2009;
Maccarrone et al., 2008), which is probably also true for dopami-
nergic terminals in our experimental models. Yet, anandamide had
a small but significant stimulatory effect on the release of dopa-
mine. This indicates that the close to significant effect of ananda-
mide in the Ca2þ assay might have resulted from the stimulation of
a small Ca2þ entry in a subpopulation of the total nerve terminal
population.
Altogether, 1) the lack of effect of capsaicin, anandamide and
R-methanandamide; 2) the agonist activity of PALDA; 3) the lack of
antagonism by iodoresiniferatoxin, SB3366791, and Ruthenium
Red; and 4) the persisting effects in the TRPV1R knockout mice all
suggest that N-acyldopamines posses additional, previously
unidentified targets to control striatal input terminals.
4.4. Possible targets of N-acyldopamines
The targets of N-acyldopamines may be cation channels in the
cell membrane. Concluding from the experiments without Kþ in
the buffer and with nifedipine, these N-acyldopamine receptors are
not sensitive to membrane potential and/or are not linked to acti-
vation of voltage-gated Ca2þ channels. Furthermore, they are highly
sensitive to the channel blocker Gd3þ whereas the Kþ-evoked
release of the two transmitters was not.
Although 2APB is a sensitizer and activator of the TRPV2R and
the TRPV3R (Hu et al., 2004), these novel N-acyldopamine receptors
do not seem to be identical with any known member of the TRPV
family: 1) we found that Gd3þwas a two-three orders of magnitude
more potent antagonist than at the TRPV1R and the TRPV2R chan-
nels (Tousova et al., 2005; Leffler et al., 2007); and 2) Ruthenium
Red, the general inhibitor of the TRPV1–6 channels, failed to prevent
the action of NADA. Additionally, anandamide and 2-AG are acti-
vators of the TRPV4R, and the lack of their putative effect in the Ca
2þ
level assays do not indicate the involvement of TRPV4Rs in the
observed effect of N-acyldopamines (Nilius et al., 2004). TRPA1
receptors can be activated by WIN55212-2 (Jeske et al., 2006)
which did not affect Ca2þ levels in our study. TRPC6 and TRPM8
receptors are blocked by 2APB, therefore these channels were also
unlikely involved in the effect of N-acyldopamines (Hu et al., 2004).
Antagonists of other common ion channels such as ionotropic
glutamate receptors, GABAA receptors, 5-HT3 serotonin and nico-
tinic receptors as well as P2X ATP receptors failed to prevent the
effect of NADA. We can also exclude the possible involvement of
metabotropic cannabinoid receptors linked to Ca2þ rise in neurons,
namely, the CB1R and the GPR55 (Lauckner et al., 2005; Pertwee,
2007) because of the rapid kinetics of Ca2þ entry and the lack of
effect of WIN55212-2 and 2-AG. The lack of functional CB1Rs instriatal dopaminergic terminals (Ko¨falvi et al., 2005; Uchigashima
et al., 2007) further argues against the involvement of CB1Rs.
Finally, we can exclude the involvement of (TASK-like) Kþ
channel blockade as a depolarizing mechanism. We have shown
previously that TASK-3 Kþ channels control hippocampal nerve
terminal membrane potential. TASK-1 and TASK-3 channels can be
blocked either by anandamide and WIN55212-2 (Maingret et al.,
2001) or by Ruthenium Red (Czirja´k and Enyedi, 2003). As in the
striatal nerve terminals neither anandamide nor Ruthenium Red
nor WIN55212-2 induced depolarization, and most importantly,
the effect of NADA persists in the absence of Kþ, we can exclude the
involvement of TASK-1 and 3 channels.
Curiously, the TRPV1R antagonist capsazepine significantly
inhibited the action of NADA on the release of dopamine. This
should account for the partial inhibition of the NADA-induced
[Ca2þ]i rise. Several present-time cation channels developed from
one common ancestor, therefore there is a relatively large struc-
tural and/or sequence similarity among many ligand- and voltage-
gated ion channels bringing about a substantial cross-reaction
among their ‘‘selective’’ ligands (Ko¨falvi, 2008). Capsazepine has
been reported to block nAChRs (Liu and Simon, 1997), HCN1
channels (Ray et al., 2003; Gill et al., 2004), and voltage-gated Ca2þ
channels (Docherty et al., 1997). Hence, it is not difficult to imagine
that if capsazepine competitively antagonizes the effect of NADA at
the TRPV1R it can do so at another related ion channel.
4.5. Possible consequences of the presynaptic action
of N-acyldopamines
Little is known about the recently discovered series of neuro-
transmitter-fatty acid conjugates such as N-arachidonoyl-glycin,
N-arachidonoyl-serotonin or N-arachidonoyldopamine. The latter
is shown to be formed and released in dopamine-rich regions
(Marinelli et al., 2007) but neither its source nor its enzymatic
pathways is delineated. N-acyldopamines may sensitize nerve
terminals at subthreshold concentrations with small increases in
nerve terminal Ca2þ levels that could amplify the size of transmitter
release upon weak axonal depolarization. Alternatively, they may
directly induce transmitter release whereby decreasing the signal-
to-noise ratio, that is, the reliability of synaptic communication.
They seem capable of inducing Ca2þ overload which may result in
Ca2þ-mediated cell death. It would be also interesting to know how
N-acyldopamine levels change in dopamine deficiency, i.e. in
Parkinson’s disease and how these changes contribute to the
development of syndromes.
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